Why Astrazeneca plc ADR (NASDAQ: AZN) Stock Should Not Be Taken For Granted By Investors In 2024

IPW

In the last trading session, 5.59 million shares of the Astrazeneca plc ADR (NASDAQ:AZN) were traded, and its beta was 0.51. Most recently the company’s share price was $70.85, and it changed around $0.72 or 1.03% from the last close, which brings the market valuation of the company to $219.67B. AZN currently trades at a discount to its 52-week high of $76.56, offering almost -8.06% off that amount. The share price’s 52-week low was $60.47, which indicates that the current value has risen by an impressive 14.65% since then. We note from Astrazeneca plc ADR’s average daily trading volume that its 3-month average coming to 6.17 million.

Astrazeneca plc ADR stock received a consensus recommendation rating of Overweight, based on a mean score of 1.68. If we narrow it down even further, the data shows that 0 out of 5 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 1 recommended AZN as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight. Astrazeneca plc ADR is expected to report earnings per share of $1.22 for the current quarter.

Astrazeneca plc ADR (NASDAQ:AZN) trade information

Instantly AZN has showed a green trend with a performance of 1.03% at the end of last trading. The performance over the last five days has remained in the green territory. The company’s shares are currently up 5.20% year-to-date, but still up 3.79% over the last five days. On the other hand, Astrazeneca plc ADR (NASDAQ:AZN) is 6.93% up in the 30-day period.

The consensus price target as assigned by Wall Street analysts is $80.5, which translates to bulls needing to increase their stock price by 11.99% from its current value. Analyst projections state that AZN is forecast to be at a low of $79 and a high of $82.

Astrazeneca plc ADR (AZN) estimates and forecasts

Astrazeneca plc ADR share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 11.00 percent over the past six months and at a 10.19% annual growth rate that is well above the industry average of 3.70%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 27.10% in revenue this quarter, and will report an increase of 22.20% in the next quarter. The year-over-year growth rate is expected to be 10.90%, up from the previous year.

Consensus estimates provided by 4 financial analysts predict the company will bring in an average of $11.83 billion in revenue for the current quarter. 3 analysts expect Astrazeneca plc ADR to make $12.44 billion in revenue for the quarter ending Jun 2024. The company’s sales for the same quarters a year ago were $10.55 billion and $10.96 billion respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 12.10%. Forecasts for the next quarter put sales growth at 13.50%.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 17.72%. Astrazeneca plc ADR earnings are expected to increase by 11.66% in 2024, but the outlook is positive 13.20% per year for the next five years.

AZN Dividends

Astrazeneca plc ADR’s next quarterly earnings report is expected to be released in May. The annual dividend yield of the stock is 2.05 percent and its annual dividend per share was 1.45. It is important to note, however, that the 2.05% dividend yield ratio should be regarded as a guide only, as many other factors should be taken into consideration before making any investment decision.